Nab-paclitaxel/danburstotug complex AP160
Term · Oncology and biomedicine · MLC-T-ONC-015403
A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, complexed with danburstotug, a human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential antineoplastic activity. Upon administration of nab-paclitaxel/danburstotug complex AP160, the danburstotug moiety specifically binds to PD-L1 and targets this formulation to PD-L1-positive tumor cells. In turn, paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of PD-L1-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and targeting by the danburstotug moiety allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types.
| Identifier | MLC-T-ONC-015403 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Nab-paclitaxel/STI-3031 complex AP160 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015403",
"term": "Nab-paclitaxel/danburstotug complex AP160",
"field": "Oncology and biomedicine",
"definition": "A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, complexed with danburstotug, a human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential antineoplastic activity. Upon administration of nab-paclitaxel/danburstotug complex AP160, the danburstotug moiety specifically binds to PD-L1 and targets this formulation to PD-L1-positive tumor cells. In turn, paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of PD-L1-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and targeting by the danburstotug moiety allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types.",
"synonyms": [
"Nab-paclitaxel/STI-3031 complex AP160"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/nab-paclitaxel-danburstotug-complex-ap160/"
}
Record 11,539 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.